New York Magazine reports that Team A-Rod has gone after Biogenesis founder Tony Bosch as a habitual cocaine user. And they have a photo that appears to be Bosch with two small bags of cocaine.
The basis for the claim is a friend of Bosch’s — who himself has a spotty past — who says that Bosch used cocaine regularly in Miami. A-Rod’s lawyers cross examined Bosch about his cocaine use in the arbitration. They were met with objections about the line of questioning from Major League Baseball’s attorneys. When Bosch answered he said “I’ll take the Fifth.”
Now, clearly, Tony Bosch’s credibility as a witness is essential here, as the case comes down to his accusations against Alex Rodriguez and his authentication and explanation of Biogenesis documents which purport to show A-Rod’s PED use. At the same time, courts rarely give much weight to — and often don’t allow — evidence relating to the past bad acts or the bad overall character of a witness as a means of challenging his credibility. Rather, you have to establish that the dirt you have on the witness directly speaks to his credibility, not just his character, habits, addictions or what have you.
I would say this is of little overall consequence in the arbitration. If A-Rod’s lawyers could make more of it maybe it would matter. Say, they could establish that Bosch was in trouble with drug lords and needed money and, well, you can tell any number of tales that could get you from drugs to lying to help Major League Baseball. But if that came out, the same source leaking the testimony to New York Magazine here would have mentioned it right? And either way, it’s pretty far-fetched.
This is all a part of A-Rod’s throw-everything-against-the-wall-and-see-what-sticks defense. It may work in the court of public opinion. It may raise secondary or tertiary questions about Anthony Bosch. But without anything more, drug use is not, in and of itself, likely to affect his overall credibility in the mind of the arbitrator.
Former Tigers infielder Casey McGehee has reportedly signed a one-year deal with the Yomiuri Giants of Nippon Professional Baseball, according to FOX Sports’ Ken Rosenthal.
It’s the fourth move the corner infielder has made in the last two seasons after seeing short-term stints with the Marlins, Giants and Tigers. He signed a minor league deal with the Tigers prior to the 2016 season, providing the club with some infield depth behind 24-year-old Nick Castellanos. When Castellanos hit the disabled list in August with a broken hand, McGehee was recalled from Triple-A Toledo for a 30-game stint and slashed .228/.260/.239 with one extra-base hit in 96 PA. His career batting line (.258/.317/.384 over eight seasons) isn’t too shabby, but his age and a long history of knee injuries puts a damper on his potential.
McGehee last appeared in the NPB circuit in 2013, when he signed a one-year, $1.5 million deal with the Tohoku Rakuten Golden Eagles. He spent the bulk of his season at the hot corner, batting an impressive .292/.396/.515 with 28 homers in 590 PA and appearing in the Eagles’ first and only championship run to date.
The deal comes with a club option for 2018, Rosenthal reports, though no figure has been specified.
Free agent left-hander Rich Hill is rumored to be entertaining a three-year, $40+ million offer from the Dodgers, reports Peter Gammons. The Boston Globe’s Nick Cafardo corroborated the report, adding that Hill could receive somewhere between $46 and $48 million from his former team.
Hill, 36, pitched to a 2.12 ERA and 3.91 FIP in back-to-back stints with the Athletics and Dodgers in 2016. While a chronic case of blisters on his pitching hand limited the frequency of his starts, he still figures to be one of the most productive and noteworthy starting pitchers on the market this winter.
The Orioles, Yankees, Red Sox, Rangers and Astros have all been mentioned as potential suitors for the left-hander’s services, though Orioles’ GM Dan Duquette said the club has yet to make a play for Hill and ESPN’s Jim Bowden pointed out that the Red Sox are less involved in trade talks than other interested parties.